Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab + Regorafenib in MSS Colorectal Cancer
NCT03081494Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab in metastatic colorectal cancer (mCRC), sponsored by Novartis. Primary endpoint: Incidence of Dose-limiting toxicity at 8 weeks. Started Jun 2017; status: completed.
02
Drugs
spartalizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03081494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081494.